 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...3233343536373839404142...208209» |
- | Itari (linperlisib) / Shanghai YingLi Pharma
New P2 trial: Linperlisib in the Treatment of aPRCA (clinicaltrials.gov) - Jun 27, 2025
P2, N=15, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- || HRS-5965 / Jiangsu Hengrui Pharma
New P1 trial: A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects (clinicaltrials.gov) - Jun 27, 2025
P1, N=16, Not yet recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
- | Avastin (bevacizumab) / Roche, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer (clinicaltrials.gov) - Jun 27, 2025
P3, N=424, Recruiting, Sponsor: Tongji Hospital
Not yet recruiting --> Recruiting
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Journal: SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. (Pubmed Central) - Jun 26, 2025
The above results suggested that SHR-A1811 is a potential best-in-class anti-HER2 ADC with a highly permeable payload, optimized DAR, great potency and better safety profiles. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC.
- || recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Enrollment closed: Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers (clinicaltrials.gov) - Jun 26, 2025
P1, N=46, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC. Not yet recruiting --> Active, not recruiting
- || P2 data, Journal, PD(L)-1 Biomarker: Camrelizumab Combined with Lenvatinib and RALOX-Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma (Cal Era): A Prospective, Single-Arm, Phase II Trial. (Pubmed Central) - Jun 26, 2025
P2
The triple regimen of camrelizumab, lenvatinib, and RALOX-HAIC exhibited notable antitumor capabilities and acceptable tolerability in patients with advanced HCC. Moreover, baseline levels of IL-2, CXCL13, and CCL19 may function as predictive indicators of the response to this first-line therapeutic strategy.
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Enrollment open: SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (clinicaltrials.gov) - Jun 26, 2025
P2, N=180, Recruiting, Sponsor: Henan Cancer Hospital
Moreover, baseline levels of IL-2, CXCL13, and CCL19 may function as predictive indicators of the response to this first-line therapeutic strategy. Not yet recruiting --> Recruiting
- || AiRuiKa (camrelizumab) / HLB Bio Group, albumin-bound paclitaxel / Generic mfg.
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Multi-Center Phase II Study of Nab-Paclitaxel Plus Camrelizumab Versus Nab-Paclitaxel Alone as Second-Line Treatment for Advanced Gastric Cancer. (Pubmed Central) - Jun 24, 2025
Cam-NP significantly improved ORR and PFS compared to NP as a second-line treatment for advanced gastric adenocarcinoma. Larger studies and biomarker exploration are needed to validate these findings.
- || Retrospective data, Review, Journal: Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis. (Pubmed Central) - Jun 24, 2025
Immune checkpoint inhibitors (ICIs) combined with etoposide-platinum are recommended as the standard first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)...The drug combination patterns included ipilimumab, durvalumab, adebrelimab, atezolizumab, socazolimab, pembrolizumab, serplulimab, tislelizumab, toripalimab, durvalumab + tremelimumab, tiragolumab + atezolizumab, benmelstobart + anlotinib, bevacizumab + atezolizumab, anlotinib, bevacizumab in combination with chemotherapy...The toxicity of ICI + Antiangio + Chemo was acceptable but needed careful attention. These findings clarified the roles of ICIs and antiangiogenic agent-based treatment strategies in this population.
- | Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review. (Pubmed Central) - Jun 24, 2025
This case underscores the potential efficacy of combining immune checkpoint inhibitors with small-molecule multi-targeted tyrosine kinase inhibitors in treating advanced SCC of the lung after progression on first-line therapy. The complementary mechanisms of immune modulation and tumor microenvironment normalization may offer an effective strategy for addressing immune resistance in SCC.
- | AiTan (rivoceranib) / HLB Bio Group
Journal, Checkpoint inhibition, Real-world evidence: The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study. (Pubmed Central) - Jun 24, 2025
Safety profiles were comparable between groups, with no significant increase in severe adverse events with combination therapy. Apatinib combined with ICIs demonstrated improved survival outcomes compared to apatinib monotherapy in AGC, particularly for patients with liver metastasis, without increasing severe toxicity.
- | oxaliplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group
Journal: Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer. (Pubmed Central) - Jun 24, 2025
Hematocrit < 33% and hemoglobin < 107 g/L are risk factors for chemotherapy failure in patients with advanced gastric cancer. They are associated with poorer prognosis and reduced 3-year survival rates.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy. (Pubmed Central) - Jun 24, 2025
All adverse events were manageable, and no treatment-related deaths occurred. HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC.
- ||||| HRS-7535 / Kailera Therapeutics
Enrollment closed: A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity (clinicaltrials.gov) - Jun 23, 2025
P3, N=556, Active, not recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
HAIC combined with apatinib/camrelizumab is effective and safe in the treatment of recurrent HCC after hepatectomy, which may be a promising treatment for recurrent HCC. Recruiting --> Active, not recruiting
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
Journal: Recaticimab: First Approval. (Pubmed Central) - Jun 23, 2025
Recaticimab received its first approval on 8 January 2025 in China, as an adjunct to diet, in combination with statins (with or without other lipid-lowering therapies) in adults with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia who have not achieved their low-density lipoprotein cholesterol (LDL-C) target despite receiving moderate or higher doses of statins, and for use as monotherapy in adults with non-familial hypercholesterolemia and mixed dyslipidemia to reduce LDL-C, total cholesterol, and apolipoprotein B levels. This article summarizes the milestones in the development of recaticimab leading to this first approval for hypercholesterolemia and mixed dyslipidemia.
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects (clinicaltrials.gov) - Jun 23, 2025
P1, N=57, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
This article summarizes the milestones in the development of recaticimab leading to this first approval for hypercholesterolemia and mixed dyslipidemia. Active, not recruiting --> Completed
- ||| imrecoxib/tramadol (HR18042) / Jiangsu Hengrui Pharma
Trial completion: A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth. (clinicaltrials.gov) - Jun 22, 2025
P2, N=187, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| IDE849 / Ideaya Biosci
New P2 trial: A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov) - Jun 20, 2025
P2, N=120, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- || Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Clinical, Journal: Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial. (Pubmed Central) - Jun 19, 2025
P4
Low-dose hetrombopag demonstrated efficacy equivalent to high-dose, offering a cost-effective strategy to improve transplant outcomes. Trial Registration: ChiCTR2200057764.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Case report of complete remission in two patients with Barcelona stage C hepatocellular carcinoma treated with apatinib combined with camrelizumab. (Pubmed Central) - Jun 19, 2025
This report presents two cases of Barcelona Clinic Liver Cancer (BCLC) stage C HCC that achieved complete remission following treatment with apatinib plus camrelizumab. According to the Response Evaluation Criteria in Solid Tumors, both patients achieved complete response, allowing for drug discontinuation.
- || remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Clinical: Corrigendum to "The efficacy and safety of remimazolam tosilate compared with propofol for endoscopic retrograde cholangiopancreatography under monitored anesthesia care: A single-center randomized controlled clinical trial" [Heliyon Volume 10, Issue 19, October 2024, Article e38349]. (Pubmed Central) - Jun 19, 2025
According to the Response Evaluation Criteria in Solid Tumors, both patients achieved complete response, allowing for drug discontinuation. [This corrects the article DOI: 10.1016/j.heliyon.2024.e38349.].
- ||||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Biomarker, New P4 trial: A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment (clinicaltrials.gov) - Jun 18, 2025
P4, N=350, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Journal: Extended progression-free survival after combination treatment with anlotinib and S-1 in refractory advanced esophageal cancer: A case report. (Pubmed Central) - Jun 18, 2025
Tumor progression continued after multiline chemotherapy with paclitaxel, platinum and irinotecan; immunotherapy with camrelizumab; and radiotherapy...As fourth-line therapy, anlotinib was administered in combination with S-1. Thereafter, the patient's progression-free survival was 16.7 months, indicating that anlotinib combined with S-1 may be effective in refractory advanced esophageal cancer.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - Jun 18, 2025
P2, N=30, Recruiting, Sponsor: Ruijin Hospital
- |||||| SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (clinicaltrials.gov) - Jun 18, 2025
P2/3, N=840, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Thereafter, the patient's progression-free survival was 16.7 months, indicating that anlotinib combined with S-1 may be effective in refractory advanced esophageal cancer. Not yet recruiting --> Recruiting
- ||||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma
New P4 trial: Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial?HERO -aCKD? (clinicaltrials.gov) - Jun 18, 2025
P4, N=429, Not yet recruiting, Sponsor: First Affiliated Hospital of Wannan Medical College
- | AiTan (rivoceranib) / HLB Bio Group
Journal: The alkylglycerone phosphate synthase sustains the resistance of gastric cancer cells to ferroptosis induced by Apatinib. (Pubmed Central) - Jun 17, 2025
Apatinib-resistant gastric cancer cells exhibit reduced expression of the transcription factor ELK1, which regulates the expression of AGPS. This reduction contributes to the resistance and malignancy of gastric cancer cells.
- || Herceptin (trastuzumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial. (Pubmed Central) - Jun 17, 2025
This reduction contributes to the resistance and malignancy of gastric cancer cells. Neoadjuvant camrelizumab plus trastuzumab and chemotherapy demonstrated favorable response and tolerable safety in HER2-positive G/GEJ adenocarcinoma.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion: AMBITION: Neoadjuvant Therapy for Locally Advanced Colon Cancer (clinicaltrials.gov) - Jun 17, 2025
P2, N=64, Completed, Sponsor: Zhejiang University
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy demonstrated favorable response and tolerable safety in HER2-positive G/GEJ adenocarcinoma. Recruiting --> Completed
- | M9466 / EMD Serono
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov) - Jun 16, 2025
P1, N=0, Withdrawn, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Completed N=54 --> 0 | Trial completion date: Oct 2027 --> May 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2027 --> May 2025
- |||||||| HRS-8080 / Jiangsu Hengrui Pharma
New P3 trial: A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Jun 16, 2025
P3, N=200, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Assessing the effectiveness of camrelizumab plus anti-angiogenesis drug for the treatment of advanced liver cancer: a single?center retrospective study. (Pubmed Central) - Jun 16, 2025
The predominant treatment-emergent adverse events observed during therapy included: elevated total bilirubin in 28 cases (46.7%), proteinuria in 19 cases (31.7%), gastrointestinal reactions in 19 cases (31.7%), and thrombocytopenia in 16 cases (26.7%). Based on real-world data, individuals with intermediate and advanced primary liver cancer undergoing systemic therapy may benefit from camrelizumab combined with anti-angiogenic drugs.
- || HRS-7535 / Kailera Therapeutics
Enrollment open: Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - Jun 16, 2025
P1, N=24, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Based on real-world data, individuals with intermediate and advanced primary liver cancer undergoing systemic therapy may benefit from camrelizumab combined with anti-angiogenic drugs. Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Checkpoint inhibition: High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors. (Pubmed Central) - Jun 16, 2025
Furthermore, patients had higher ADA levels after the early phase of treatment, specifically in the first three cycles with camrelizumab. It found that the higher the ADA concentration, the lower the serum camrelizumab concentration.
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Journal, HEOR, Cost-effectiveness: Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer. (Pubmed Central) - Jun 13, 2025
It found that the higher the ADA concentration, the lower the serum camrelizumab concentration. This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
Journal: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting. (Pubmed Central) - Jun 13, 2025
Diarrhea (39.2%), white blood cell count decreased (33.0%), and myelosuppression (18.6%) as the most frequent ones. Following the first- and second-line of treatment, inetetamab- containing combinations demonstrated promising clinical activity and a manageable safety profile in patients with HER2-positive MBC, especially in the first-line treatment.
- ||| ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Clinical, P2/3 data, Journal: Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III Trial. (Pubmed Central) - Jun 13, 2025
Ivarmacitinib 4 mg significantly improved the signs and symptoms of AS at week 12 compared to placebo, with sustained efficacy through 24 weeks and a tolerable safety profile. These findings support ivarmacitinib 4 mg as a new treatment option for active AS.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 13, 2025
P2, N=100, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- ||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed, Trial primary completion date: HRS9531-302: the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes? Inadequately Controlled With Diet and Exercise Alone (clinicaltrials.gov) - Jun 12, 2025
P3, N=218, Active, not recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
These findings support ivarmacitinib 4 mg as a new treatment option for active AS. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2026 --> May 2025
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P3 trial: ESO-Nanjing12: Immunochemotherapy (clinicaltrials.gov) - Jun 12, 2025
P3, N=79, Enrolling by invitation, Sponsor: Ye jinjun
- | Journal: Plasma IFN-? may predict pyrotinib efficacy in patients with HER2-positive advanced breast cancer. (Pubmed Central) - Jun 12, 2025
Additionally, plasma IFN-? has potential prognostic value in patients with HER2-positive ABC treated with pyrotinib.
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution (clinicaltrials.gov) - Jun 12, 2025
P1, N=120, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
has potential prognostic value in patients with HER2-positive ABC treated with pyrotinib. Recruiting --> Completed
- ||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed, Monotherapy: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (clinicaltrials.gov) - Jun 12, 2025
P3, N=884, Active, not recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Retrospective data, Review, Journal, Adverse events: Post-Treatment Adverse Events Ranking in Targeted Immunotherapy for Hepatocellular Carcinoma: A Network Meta-Analysis based on Risk Probability Assessment. (Pubmed Central) - Jun 11, 2025
Recruiting --> Active, not recruiting Cabozantinib, camrelizumab, and their combination therapy for HCC are associated with a higher incidence of common adverse reactions, whereas durvalumab, lenvatinib, and their combination therapy are less likely to cause common adverse effects.
- || Review, Journal: Targeting TIME in Advanced Hepatocellular Carcinoma: Mechanisms of Drug Resistance and Treatment Strategies. (Pubmed Central) - Jun 11, 2025
This article reviews the mechanism of TIME promoting drug resistance, discusses the influence of current systemic HCC treatment drugs on TIME, and evaluates how these TIME changes affect the efficacy of treatment. A deeper understanding of the interaction between TIME and systemic treatment drugs may be beneficial to enhance the treatment effect, mitigate drug resistance of advanced HCC, and ultimately improve the prognosis of patients.
- | Journal: Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma. (Pubmed Central) - Jun 11, 2025
Obesity's role in anti-programmed cell death protein-1 therapy appears could have a benefit, while its effects on other treatments, such as anti-vascular endothelial growth factor therapy, may reduce efficacy. Further research is needed to explore how obesity influences the effectiveness of other most common immunotherapies like nivolumab, pembrolizumab, and bevacizumab, and whether weight loss as well as weight-loss related sarcopenia impacts these benefits.
- | Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma, bicalutamide / Generic mfg.
Journal, HEOR, Cost-effectiveness: Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov's model-based evaluation. (Pubmed Central) - Jun 11, 2025
Scenario analysis indicated that rezvilutamide could be considered cost-effective if priced below $705.46 per cycle. From the perspective of Chinese payers, rezvilutamide plus ADT appears to be a less cost-effective strategy compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.
- |||||||||| HRS-5965 / Jiangsu Hengrui Pharma
New P3 trial: A Trial of HRS-5965 Capsule in Primary IgA Nephropathy (clinicaltrials.gov) - Jun 11, 2025
P3, N=378, Not yet recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Jun 10, 2025
P2, N=44, Completed, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Journal: Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. (Pubmed Central) - Jun 10, 2025
In the HR-positive subgroup, the closeness and aggregation of HER2-strong-positive tumor cells, as opposed to a uniform distribution, are linked to a lower response rate and HER2 luminal-like (HER2-LUM) subtype, which more closely resembles HR+/HER2- breast cancer. In addition, we develop a clinically practical predictive model capable of predicting neoadjuvant treatment responses to SHR-A1811 and other novel ADCs based on clinicopathological characteristics and pathological images.